Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology · Neuroendocrine Tumors

How Does PRRT (Lutathera) Work for Neuroendocrine Tumors?

At a Glance

Peptide Receptor Radionuclide Therapy (PRRT) with Lutathera is a targeted radiation treatment for neuroendocrine tumors (NETs). It works by acting as a 'key' that binds to somatostatin receptors on cancer cells, delivering radiation directly inside the tumor to destroy it.

In this answer

5 sections

01

How PRRT Works

02

How Do I Know If I Am a Candidate?

03

Treatment Schedule and Somatostatin Analogs

04

What to Expect on Treatment Day

05

Long-Term Safety and At-Home Precautions

Peptide Receptor Radionuclide Therapy (PRRT) is an advanced form of targeted radiation used to treat neuroendocrine tumors (NETs). The most common type of PRRT is a drug called Lutathera (177Lu-DOTATATE) [1]. Unlike traditional radiation that beams energy from outside the body, PRRT works from the inside out. It combines a targeting protein (a peptide) with a small amount of radioactive material. When injected into the bloodstream, the targeting protein acts like a homing device, seeking out specific “locks” (receptors) found on the surface of many neuroendocrine tumor cells. Once it binds to the cell, the radiation is delivered directly into the tumor, damaging the cancer cells while minimizing harm to surrounding healthy tissue [2].

How PRRT Works

Neuroendocrine tumors often have high numbers of specialized proteins on their surface called somatostatin receptors (SSTRs) [1]. You can think of these receptors as unique locks that only accept a specific key.

In PRRT, the drug (such as Lutathera) acts as that key. It is designed to bind tightly to the somatostatin receptors [2]. Because the drug is carrying a radioactive particle (Lutetium-177), it safely travels through your bloodstream until it attaches to the tumor cells [3]. Once attached, the radiation penetrates the tumor to destroy the cancer cells from within [4]. This highly targeted approach is what makes PRRT effective for certain NETs, especially those that cannot be removed by surgery or have spread to other parts of the body [5].

How Do I Know If I Am a Candidate?

Because PRRT relies entirely on somatostatin receptors to find the cancer, it will only work if your tumor has plenty of these receptors [1]. To figure out if you are a candidate, your care team will use a specialized imaging test, usually a DOTATATE PET/CT scan (such as a Gallium-68 or Copper-64 DOTATATE scan) [6][7].

During this scan, a small amount of a safe radioactive tracer is used to locate the somatostatin receptors in your body [8]. If your tumors have a high density of these receptors, they will absorb the tracer and appear very bright—often described as “lighting up” or showing “avid uptake”—on the scan images [9][10].

If your tumors “light up” brightly, it means they are SSTR-positive, which is the primary requirement for PRRT [11]. The FDA has approved Lutathera for adults and pediatric patients 12 years and older with SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which are NETs that start in the gut or pancreas [12][13].

Treatment Schedule and Somatostatin Analogs

A standard course of PRRT is typically given as a series of 4 intravenous (IV) infusions, spaced about 8 weeks apart [14]. Because many NET patients already take monthly somatostatin analog (SSA) injections (like octreotide or lanreotide) to manage their disease, your care team will carefully coordinate your shots around your PRRT schedule. While traditional protocols often require a “washout” period before your scan or treatment, emerging evidence suggests your doctor may simply adjust the timing of your SSAs based on your specific situation to ensure they do not interfere with the treatment [15][16].

What to Expect on Treatment Day

On the day of your infusion, expect to be at the clinic for most of the day [14]. Because the radiation is cleared by your organs, there are specific steps taken to protect your body [17].

  • Protecting Your Kidneys: You will receive an intravenous (IV) solution of amino acids before, during, and after the PRRT infusion to protect your kidneys from radiation [14][18]. This drip can take several hours.
  • Managing Nausea: The amino acid solution, rather than the radiation itself, often causes nausea. Your care team will provide anti-nausea medications (antiemetics) beforehand. Many clinics now use modified amino acid formulations (with lower concentrations of arginine and lysine) that significantly reduce this severe nausea [14].

Long-Term Safety and At-Home Precautions

While PRRT is generally considered safe and effective, it is a radioactive treatment with important considerations [17].

  • Radiation Safety at Home: After you leave the clinic, you will still emit a small amount of radiation for a short time. For several days, you will need to follow strict safety protocols at home, such as sleeping in a separate bed, avoiding close physical contact with family members (especially pregnant women and children), and using a separate bathroom [1][14].
  • Monitoring Blood Counts: The radiation can temporarily affect your bone marrow [18]. This may cause drops in your white blood cells, red blood cells, or platelets, requiring frequent blood tests [19][20].
  • Rare Long-Term Risks: Although severe long-term complications are rare, a small percentage of patients (around 2-3%) may develop secondary blood cancers, such as Myelodysplastic Syndrome (MDS) or acute myeloid leukemia (AML), months or years after treatment [21][22]. Your care team will monitor your blood counts long-term to watch for any persistent issues [23].

Common questions in this guide

How do I know if I am a candidate for PRRT?
To be a candidate for PRRT, your neuroendocrine tumor must have high numbers of somatostatin receptors. Your care team will use a DOTATATE PET/CT scan to see if your tumors absorb a radioactive tracer, which indicates they are a good match for the treatment.
What is the treatment schedule for Lutathera?
A standard course of PRRT involves a series of four intravenous (IV) infusions. These treatments are typically administered at a clinic and spaced about eight weeks apart.
Why do I need an amino acid drip during PRRT?
During your infusion, you will receive an IV solution of amino acids to protect your kidneys from radiation. This amino acid drip, rather than the radiation itself, is the primary cause of nausea during treatment, which your care team will help manage with medications.
What radiation safety precautions will I need to take at home?
After leaving the clinic, you will emit a small amount of radiation for a short period. For several days, you must follow strict safety protocols at home, such as sleeping in a separate bed, using a separate bathroom, and avoiding close contact with pregnant women and children.
Will PRRT affect my blood cell counts?
The radiation from PRRT can temporarily affect your bone marrow, leading to drops in your white blood cells, red blood cells, or platelets. You will need frequent blood tests during and after your treatment to monitor these counts and watch for any rare, long-term issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my most recent DOTATATE scan show enough 'uptake' to make me a good candidate for PRRT?
  2. 2.Based on my living situation, exactly how many days will I need to isolate from my family and sleep in a separate bed after each treatment?
  3. 3.How do we need to time my regular somatostatin analog (SSA) injections around my PRRT infusions?
  4. 4.What is the follow-up plan to measure if the PRRT is working?
  5. 5.How long will we need to monitor my blood counts after I finish all my cycles to check for bone marrow issues or secondary blood conditions?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Are Endocrine Tumors Benign or Malignant?Are Endocrine Tumors Hereditary? Testing GuideWhat is a Carcinoid Crisis During Surgery?What Are the Symptoms of Carcinoid Syndrome?Endocrine Tumors: Why Do They Cause Weight Gain & High BP?What Foods to Avoid Before an Endocrine Tumor Test?What Is a Functional vs Non-Functional Endocrine Tumor?Why Do I Need a DOTATATE PET Scan for NETs?Will I Need Hormone Therapy After Gland Removal?Who Treats Endocrine Tumors? Your Care Team ExplainedNET vs. NEC Neuroendocrine Tumors: What's the Difference?Why Is Biopsy Dangerous for Suspected Pheochromocytoma?Why Does MEN2 Require Preventative Thyroid Surgery?Somatostatin Analogs (SSAs) for NETs: What to ExpectWhat is the Ki-67 Index in Neuroendocrine Tumors (NETs)?

References

References (23)
  1. 1

    Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy.

    Hennrich U, Kopka K

    Pharmaceuticals (Basel, Switzerland) 2019; (12(3)) doi:10.3390/ph12030114.

    PMID: 31362406
  2. 2

    Two Birds with One Stone: Skull Base Meningioma and Jugulotympanic Paragangliomas with Somatostatin Receptor Positron Emission Tomography.

    Treglia G, Raditchkova M, Giovanella L, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(9)) doi:10.3390/diagnostics11091669.

    PMID: 34574010
  3. 3

    Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

    Brabander T, van der Zwan WA, Teunissen JJM, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(16)):4617-4624 doi:10.1158/1078-0432.CCR-16-2743.

    PMID: 28428192
  4. 4

    Safety and outcomes of 177 Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia.

    Lin E, Chen T, Little A, et al.

    Internal medicine journal 2019; (49(10)):1268-1277 doi:10.1111/imj.14336.

    PMID: 31062490
  5. 5

    Overview and Current Status of Peptide Receptor Radionuclide Therapy.

    Bushnell DL, Bodeker KL

    Surgical oncology clinics of North America 2020; (29(2)):317-326 doi:10.1016/j.soc.2019.11.005.

    PMID: 32151363
  6. 6

    Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.

    Kandathil A, Subramaniam RM

    PET clinics 2023; (18(2)):189-200 doi:10.1016/j.cpet.2022.11.001.

    PMID: 36585339
  7. 7

    64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial.

    Delpassand ES, Ranganathan D, Wagh N, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020; (61(6)):890-896 doi:10.2967/jnumed.119.236091.

    PMID: 31924723
  8. 8

    68Ga-DOTATATE PET-CT imaging in carotid body paragangliomas.

    Şimşek DH, Şanlı Y, Kuyumcu S, et al.

    Annals of nuclear medicine 2018; (32(4)):297-301 doi:10.1007/s12149-018-1242-3.

    PMID: 29468487
  9. 9

    68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit.

    Lybik N, Wale DJ, Wong KK, et al.

    Clinical nuclear medicine 2021; (46(6)):505-506 doi:10.1097/RLU.0000000000003589.

    PMID: 33782291
  10. 10

    The value of 68 Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series.

    Liu KY, Goldrich DY, Ninan SJ, et al.

    Head & neck 2021; (43(6)):E30-E40 doi:10.1002/hed.26695.

    PMID: 33786927
  11. 11

    Enhancing Diagnostic Accuracy in Sinonasal Neuroendocrine Tumors: The Case for DOTATATE PET Over FDG PET.

    Sabbaj M, Kanwar A, Grayson JW, et al.

    International forum of allergy & rhinology 2025; (15(10)):1023-1027 doi:10.1002/alr.70001.

    PMID: 40679114
  12. 12

    Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

    Hope TA, Pavel M, Bergsland EK

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(24)):2818-2829 doi:10.1200/JCO.22.00176.

    PMID: 35649195
  13. 13

    Expanding the therapeutic horizon of 177Lu-DOTATATE: a review of current evidence.

    Minamimoto R, Kato K, Iwano S, et al.

    Nagoya journal of medical science 2025; (87(4)):607-631 doi:10.18999/nagjms.87.4.607.

    PMID: 41550194
  14. 14

    Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.

    Boucher JE, Sommers R

    Clinical journal of oncology nursing 2018; (22(5)):565-568 doi:10.1188/18.CJON.565-568.

    PMID: 30239510
  15. 15

    Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide.

    Low HC, Tay YS, Ong SYK, et al.

    Clinical nuclear medicine 2023; (48(12)):1086-1088 doi:10.1097/RLU.0000000000004906.

    PMID: 37844418
  16. 16

    The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE.

    Veerman CHAM, Siebinga H, de Vries-Huizing DMV, et al.

    European journal of nuclear medicine and molecular imaging 2023; (50(5)):1434-1441 doi:10.1007/s00259-022-06094-z.

    PMID: 36598536
  17. 17

    Interim PET/CT with [68Ga]Ga-DOTA-peptides in NET prognostication: is Δ-radiomics the next frontier?

    Filippi L, Schillaci O

    European radiology 2025; (35(5)):2556-2558 doi:10.1007/s00330-024-11117-4.

    PMID: 39436412
  18. 18

    An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE.

    Kovan B, Özkan ZG, Demir B, et al.

    Cancer biotherapy & radiopharmaceuticals 2022; (37(1)):17-22 doi:10.1089/cbr.2021.0071.

    PMID: 34134512
  19. 19

    Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy.

    Persson M, Hindorf C, Ardenfors O, et al.

    EJNMMI research 2024; (14(1)):13 doi:10.1186/s13550-024-01077-7.

    PMID: 38319478
  20. 20

    Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

    Bergsma H, van Lom K, Raaijmakers MHGP, et al.

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2018; (59(3)):452-458 doi:10.2967/jnumed.117.189712.

    PMID: 28775205
  21. 21

    Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.

    Chantadisai M, Kulkarni HR, Baum RP

    European journal of nuclear medicine and molecular imaging 2021; (48(5)):1390-1398 doi:10.1007/s00259-020-05127-9.

    PMID: 33247328
  22. 22

    Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.

    Goncalves I, Burbury K, Michael M, et al.

    European journal of nuclear medicine and molecular imaging 2019; (46(9)):1902-1910 doi:10.1007/s00259-019-04389-2.

    PMID: 31187162
  23. 23

    Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.

    Sonbol MB, Halfdanarson TR, Hilal T

    JAMA oncology 2020; (6(7)):1086-1092 doi:10.1001/jamaoncol.2020.0078.

    PMID: 32297906

This page provides educational information about PRRT and Lutathera. It does not replace professional medical advice. Always consult your oncologist or nuclear medicine specialist to determine if this treatment is right for your specific neuroendocrine tumor.

Get notified when new evidence is published on Tumor of endocrine glands.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.